Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual immunotherapy with Dermatophagoides pteronyssinus extract in mild to moderate asthma
2004-001965-16Phase 4Active
- Sponsor
- LETI Pharma
- Start
- Dec 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma and house dust mite allergy comparing Dermatophagoides pteronyssinus sublingual immunotherapy with Placebo (2 arms). Primary endpoint: Symptom diary score. Started Dec 2005; status: active.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2004-001965-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001965-16.